Global Pediatric Clinical Trials Market – Easy Administration of Medications
Pediatric clinical trials play a major role in modern healthcare, as pediatric clinical trials are the only criteria to launch new drugs in market for various indications that affect pediatric population and therefore pharmaceutical and biotechnological industries have been gradually shifting from in-house clinical research to contract research organization (CRO).
The global pediatric clinical trials market size was valued at US$ 9,885.7 million in 2017, and is expected to exhibit a CAGR of 8.8% over the forecast period (2018 – 2026).
Figure 1. Global Pediatric Clinical Trials Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2018)
Robust product pipeline, increasing approval of new pediatric drugs and high outsourcing for drug are factors driving growth of the market
Increasing number of drugs under clinical stage of development in order to cater to unmet medical needs for pediatric patient population is expected to boost the market growth. According to Pharmaceutical Research and Manufacturers’ Association (PHRMA) data in 2018, over 1,300 industry-sponsored pediatric clinical trials are underway across a variety of therapeutic areas, including diseases where there is significant unmet need such infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer. Furthermore, robust product pipeline and increasing approval of new pediatric drugs is expected to boost the market growth. For instance, in August 2018, Biocodex received U.S. FDA approval for Diacomit (stiripentol) for the treatment of seizures associated with Dravet syndrome. Similarly, in October 2018, Regeneron Pharmaceuticals received U.S. FDA approval for Dupixent (dupilumab) for the treatment of moderate-to-severe asthma.
Moreover, in December 2018, Stemline Therapeutics, received U.S. FDA approval for Elzonris (tagraxofusp-erzs) for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatrics. In June 2018, GW Pharmaceuticals received U.S. FDA approval for Epidiolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.
However, high termination percentage of pediatric clinical trials due to several reasons is expected to hinder growth of the pediatric clinical trials market. Pediatric trials have high percentage of failure due to reasons such as patient accrual. Other issues include, behavioral problem and trial conduct issues such as inaccurate dosing, difficulty in formulation, and informative termination along with regulatory issues and drug toxicity during clinical trials. According to U.S. FDA, around 25 - 40% of pediatric trials fail to establish safety, efficacy, and result in a labeled indication for pediatric use, which results in their termination.
Figure 2. Global Pediatric Clinical Trials Market Share (%), by Study Design, 2018 and 2026
Source: Coherent Market Insights Analysis (2018)
Increasing prevalence of chronic diseases in pediatric population in North America is expected to bolster the market growth
North America is expected to hold dominant position in the global pediatric clinical trials market, owing to high prevalence of chronic diseases in pediatric population and increasing number of clinical trials conducted in the U.S. Pediatric population is one of the most vulnerable groups to various diseases such as polio, epilepsy, encephalitis, asthma, chronic obstructive pulmonary disease, (COPD) and other respiratory diseases. Other diseases also include, cancer, diabetes, diarrhea, leukemia, anemia, chronic kidney disease, and other rare diseases that result in substantial disease burden worldwide. Increasing demand for new vaccines and other biologic products to tackle various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is also expected to boost the market growth. According to the World Health Organization (WHO) 2018, around 86% of infants are vaccinated against 26 diseases worldwide. However, around 19.5 million children are unvaccinated leading to death of 2-3 million children annually. Innovative approaches such as micro-needle vaccine can be utilized after due trial for safety and efficacy.
Similarly, according to the Centers for Disease Control and Prevention (CDC) factsheet in 2018, around 470,000 children had active epilepsy in the U.S., accounting for around 0.6% of children aged 0-17 years.
Major players operating in the global pediatric clinical trials market include, Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc., Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Shire plc., and Vertex Pharmaceuticals Inc.